Barclays Biotech Analyst Ellie Merle previews this weekend's highly anticipated cancer vaccine data from Merck and Moderna at ESMO
She says that consensus is a hazard ratio of 0.6 and that degrees of success could be viewed whether the data comes in lower or higher than that.









.png)